Source-grounded facts extracted from Oaktree Acquisition Corp. III Life Sciences's SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Thomas Sweeney was appointed as Chief Financial Officer at Oaktree Acquisition Corp. III Life Sciences.
“On June 3, 2025, the Board appointed Thomas Sweeney as new Chief Financial Officer (principal accounting and principal financial officer) of the Company, effective immediately.”
Courtney Conigliaro resigned as Chief Financial Officer at Oaktree Acquisition Corp. III Life Sciences.
“On June 3, 2025, Courtney Conigliaro notified the board of directors (the "Board") of Oaktree Acquisition Corp. III Life Sciences (the "Company") of her resignation as Chief Financial Officer of the Company.”
Zaid Pardesi was appointed as director at Oaktree Acquisition Corp. III Life Sciences.
“and (ii) Zaid Pardesi, the Company’s Chief Executive Officer, as a director of the Company.”
Aman Kumar was appointed as chairman of the board at Oaktree Acquisition Corp. III Life Sciences.
“the Board appointed (i) Aman Kumar, currently a director of the Company, as the new chairman of the Board”
John Frank resigned as director at Oaktree Acquisition Corp. III Life Sciences.
“On January 6, 2025, John Frank resigned from the board of directors (the “Board”) of Oaktree Acquisition Corp. III Life Sciences (the “Company”).”
Oaktree Acquisition Corp. III Life Sciences: Adopted Amended and Restated Memorandum and Articles of Association in connection with IPO (effective 2024-10-23).
“On October 23, 2024 and in connection with the IPO, the Company adopted its Amended and Restated Memorandum and Articles of Association.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.